Methods for preparing aldolases, enzyme compositions, and 5-substituted pyrrole-2-carboxylic acid compounds

The use of an enzyme combination of aldolase and transaminase to catalyze the mild and efficient condensation of bromoethylone compounds and keto acids to generate 5-substituted pyrrole-2-carboxylic acid compounds solves the problem of large-scale production in existing technologies and achieves efficient and green compound preparation.

CN123107976APending Publication Date: 2026-11-17SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202510632688.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-05-16
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing biosynthetic methods are insufficient to meet the large-scale production requirements of various 5-substituted pyrrole-2-carboxylic acid compounds, while chemical synthesis methods suffer from problems such as high temperature and high pressure or heavy metal catalysts.

Method used

Aldolase and its enzyme composition are used to catalyze the mild and efficient condensation of bromoethylone compounds and keto acids through appropriate amino acid sequence design, generating α-keto acid intermediates, which are then converted into 5-substituted pyrrole-2-carboxylic acid compounds by transaminase.

Benefits of technology

It enables the green and efficient preparation of a variety of 5-substituted pyrrole-2-carboxylic acid compounds, with broad substrate applicability and high catalytic efficiency, making it suitable for large-scale production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123107976A_ABST
    Figure CN123107976A_ABST
Patent Text Reader

Abstract

The application relates to the technical field of bioengineering, in particular to a preparation method of an aldolase, an enzyme composition thereof, a nucleic acid molecule, a recombinant expression vector, an expression cassette or construct, a host, a 5-substituent-pyrrole-2-carboxylic acid compound or a pharmaceutically acceptable salt thereof. The preparation method uses aldolase and transaminase to catalyze substitution-transamination reaction of bromoacetone compounds, sodium pyruvate and glutamic acid, so that mild biosynthesis of the 5-substituent-pyrrole-2-carboxylic acid compound is realized.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This application relates to the field of bioengineering technology, and in particular to a method for preparing an aldolase, an enzyme composition, a nucleic acid molecule, a recombinant expression vector, an expression cassette or construct, a host, a 5-substituted pyrrole-2-carboxylic acid compound or a pharmaceutically acceptable salt thereof. Background Technology

[0002] 5-Substituted-pyrrole-2-carboxylic acids are a class of organic molecules with important functions and applications, spanning fields such as medicine, materials science, agricultural chemistry, and biochemistry. In drug development, 5-Substituted-pyrrole-2-carboxylic acids possess unique advantages due to their structural diversity. Their cyclic structures impose strict conformational constraints on the skeleton, effectively enhancing the steric stability of the molecule. The carboxylic acid group can enhance the binding affinity to targets, and the pyrrole ring can mimic the structure of natural neurotransmitters, making them suitable for developing antidepressant or antiepileptic drugs. The substituent at the 5-position (such as an aryl or heterocyclic group) can interfere with tumor cell proliferation through interactions with DNA or proteases. Therefore, developing methods for preparing 5-Substituted-pyrrole-2-carboxylic acids is of great significance.

[0003] The structure of 5-substituted-pyrrole-2-carboxylic acid compounds consists of a pyrrole ring, a carboxylic acid at position 2, and a substituent at position 5. Constructing the pyrrole ring is the core step in the preparation of these compounds. Chemical synthesis methods for pyrrole rings mainly include the following strategies: Paal-Knorr pyrrole synthesis, Hantzsch pyrrole synthesis, metal-catalyzed coupling and cyclization, and multi-component reaction methods (such as the Gewald reaction). Although chemical synthesis methods are relatively mature, given that they generally require high-temperature or high-pressure reaction conditions, or the use of heavy metal catalysts or toxic reagents, the development of biosynthetic methods remains of great significance. Currently, some progress has been made in the biosynthesis of pyrrole rings. However, due to the high substrate selectivity of biosynthetic systems, specific systems are only applicable to a limited range of substrates and cannot meet the synthesis requirements of a wide variety of 5-substituted-pyrrole-2-carboxylic acid compounds. Furthermore, while biosynthetic systems are generally feasible in the laboratory, their reaction efficiency and stability are difficult to meet the needs of large-scale production.

[0004] Therefore, it is necessary to provide a biosynthetic method for 5-substituted pyrrole-2-carboxylic acid compounds that can be produced on a large scale and has broad substrate adaptability. Summary of the Invention

[0005] Based on this, one or more embodiments of this application provide a method for preparing an aldolase and its enzyme composition, a nucleic acid molecule, a recombinant expression vector, an expression cassette or construct, a host, and a 5-substituted pyrrole-2-carboxylic acid compound. The aldolase and its enzyme composition, nucleic acid molecule, recombinant expression vector, expression cassette or construct, and host of this application can be used to prepare various 5-substituted pyrrole-2-carboxylic acid compounds or their pharmaceutically acceptable salts, possessing advantages such as being green, efficient, and having broad substrate applicability. Furthermore, the preparation method of the embodiments of this application can achieve gram-scale preparation, exhibiting high reaction efficiency and good stability, and has promising application prospects for large-scale production.

[0006] In a first aspect, embodiments of this application provide an aldolase, the amino acid sequence of which includes any one of (a1) to (a3):

[0007] (a1) The amino acid sequence as shown in SEQ ID No. 1;

[0008] (a2) A sequence based on the amino acid sequence shown in (a1) by substitution, deletion and / or insertion of one or more amino acids;

[0009] (a3) an amino acid sequence that has at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence homology with the amino acid sequence shown in (a1).

[0010] In the technical solutions of this application, the aldolase obtained through appropriate amino acid sequence design has a wider substrate applicability and higher catalytic efficiency, and can be used to catalyze the mild and efficient condensation of bromoethylone compounds and keto acids.

[0011] Secondly, embodiments of this application provide an enzyme composition comprising aldolase and transaminase as described above;

[0012] The amino acid sequence of the transaminase includes any one of (b1) to (b3):

[0013] (b1) An amino acid sequence as shown in SEQ ID No. 2 or SEQ ID No. 3;

[0014] (b2) A sequence based on the amino acid sequence shown in (b1) by substitution, deletion and / or insertion of one or more amino acids;

[0015] (b3) An amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence homology with the amino acid sequence shown in (b1).

[0016] In the technical solution of this application embodiment, the enzyme composition includes the aldolase as described above. The aldolase, obtained by designing a suitable amino acid sequence, catalyzes the mild and efficient condensation of bromoethyl ketone compounds and keto acids to generate an α-keto acid intermediate. The α-keto acid intermediate is converted into the corresponding 5-substituted pyrrole-2-carboxylic acid compound under the action of transaminase, thereby realizing the mild and efficient synthesis of 5-substituted pyrrole-2-carboxylic acid compounds.

[0017] Thirdly, embodiments of this application provide a nucleic acid molecule that encodes the aldolase described above.

[0018] In the technical solution of this application embodiment, the nucleic acid molecule can encode the aldolase described above. The expression product of the nucleic acid molecule, namely the aldolase, has a wider substrate applicability and higher catalytic efficiency, and can be used to catalyze the mild and efficient condensation of bromoethylone compounds and keto acids.

[0019] Fourthly, embodiments of this application provide a recombinant expression vector, expression cassette, or construct, including the nucleic acid molecules described above.

[0020] In the technical solutions of this application embodiment, the recombinant expression vector, expression cassette, or construct includes the nucleic acid molecule as described above. The recombinant expression vector, expression cassette, or construct can express the target aldolase in a suitable host. The aldolase has a wider substrate applicability and higher catalytic efficiency, and can be used to catalyze the mild and efficient condensation of bromoethylone compounds and keto acids.

[0021] Fifthly, embodiments of this application provide a host capable of transfecting or transforming recombinant expression vectors, expression cassettes, or constructs as described above.

[0022] In the technical solution of this application embodiment, the host can be transfected or transformed with the recombinant expression vector, expression cassette or construct as described above to achieve the expression of the target aldolase. The aldolase has a wider substrate applicability and higher catalytic efficiency, and can be used to catalyze the mild and efficient condensation of bromoethylone compounds and keto acids.

[0023] In a sixth aspect, embodiments of this application provide a method for preparing a 5-substituted pyrrole-2-carboxylic acid compound or a pharmaceutically acceptable salt thereof, comprising reacting the compound represented by Formula I with sodium pyruvate and glutamic acid in the presence of a cofactor and an enzyme catalyst to obtain the compound represented by Formula II;

[0024]

[0025] Ring A is selected from substituted or unsubstituted aryl or heteroaryl groups, wherein substitution refers to at least one hydrogen atom of ring A being substituted by R.a replace;

[0026] R a Each time it appears, it is independently selected from deuterium, halogen, nitro, carboxyl, hydroxyl, mercapto, amino, cyano, acyl, sulfonyl, aminoacyl, alkenyl, alkynyl, alkyl, cycloalkyl, alkoxy, aryl, or any combination of the aforementioned groups;

[0027] The enzyme catalyst comprises the aldolase and transaminase described above.

[0028] In the technical solution of this application embodiment, a substitution reaction is carried out between a bromoethylone compound of formula I and sodium pyruvate using an aldolase to generate a keto acid intermediate. Then, a transaminase catalyzes the reaction of the keto acid intermediate with glutamic acid to generate a 5-substituted pyrrole-2-carboxylic acid compound. This preparation method is simple to operate, operates under mild conditions, has high catalytic efficiency and good stereoselectivity, and can yield optically pure 5-substituted pyrrole-2-carboxylic acid compounds. Attached Figure Description

[0029] To more clearly illustrate the technical solutions in the specific embodiments of this application or the prior art, the drawings used in the description of the specific embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of this application. For those skilled in the art, other drawings can be obtained from these drawings without creative effort.

[0030] Figure 1a and Figure 1b These are schematic diagrams illustrating the routes for the biosynthesis of 5-substituted pyrrole-2-carboxylic acid compounds in the embodiments and examples of this application. Figure 1a And a schematic diagram of the routes for obtaining specific chiral 5-substituted pyrrole-2-carboxylic acid compounds using different transaminases. Figure 1b ).

[0031] Figure 2 This is a plasmid map constructed in the embodiments and examples of this application for the co-expression of aldolase and transaminase. Figure 2 In the middle, 'a' represents pACYCDuet-NahE. E285V -TyrB, Figure 2 In the middle, b is pACYCDuet-NahE E285V -MsDAT.

[0032] Figure 3 This application describes a whole-cell cascade catalytic pathway for the synthesis of 5-substituted pyrrole-2-carboxylic acid compounds. L -Ⅱ1 reaction verification (UPLC-MS detection results).

[0033] Figure 4 This application describes a whole-cell cascade catalytic pathway for the synthesis of 5-substituted pyrrole-2-carboxylic acid compounds. L -Ⅱ1 reaction process curve.

[0034] Figure 5 This application describes the use of an in vitro cascade catalytic pathway to synthesize 5-substituted pyrrole-2-carboxylic acid compounds. L -Ⅱ1 reaction process curve.

[0035] Figure 6 The yield and enantiomeric excess (ee) of the 5-substituted pyrrole-2-carboxylic acid compounds prepared in the embodiments and examples of this application are given.

[0036] Figure 7 This is a comparative diagram showing the effect of aldolases obtained by single-point mutation based on the amino acid sequence of SEQ ID No. 1 in catalytic substitution reactions in the embodiments and examples of this application.

[0037] Figure 8 This is a comparison diagram of amino acid sequences with 45% homology similarity, selected based on the amino acid sequence of SEQ ID No. 1 in the embodiments and examples of this application.

[0038] Figure 9 In the embodiments and examples of this application, the natural aldolase NahE is shown. wt A comparison of the catalytic performance of aldolase PhdJ obtained through homology screening based on the amino acid sequence shown in SEQ ID No. 1 in substitution reactions. Detailed Implementation

[0039] The present application is further described below with reference to embodiments and examples. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of the application. Furthermore, it should be understood that after reading the teachings of this application, those skilled in the art can make various alterations or modifications to this application, and these equivalent forms also fall within the protection scope of the appended claims.

[0040] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the application.

[0041] the term

[0042] Unless otherwise stated or in case of contradiction, the terms or phrases used herein shall have the following meanings:

[0043] The term "and / or" as used herein includes any one of two or more of the related listed items, as well as any and all combinations of the related listed items, including any two related listed items, any more related listed items, or a combination of all related listed items. For example, "A and / or B" includes three parallel options: A, B, and A+B.

[0044] In this document, "preferred" is only used to describe a better implementation method or embodiment, and should be understood as not constituting a limitation on the scope of protection of this application.

[0045] In this application, "further" is used to describe the purpose and indicate differences in content, but should not be construed as a limitation on the scope of protection of this application.

[0046] In this application, the terms "first aspect," "second aspect," "third aspect," "fourth aspect," "fifth aspect," and "sixth aspect," etc., are used for descriptive purposes only and should not be construed as indicating or implying relative importance or quantity, nor should they be construed as implicitly indicating the importance or quantity of the indicated technical features. Moreover, "first," "second," "third," "fourth," "fifth," and "sixth" serve only as a non-exhaustive enumeration and should be understood not to constitute a closed limitation on quantity.

[0047] In this application, the technical features described in an open-ended manner include both closed technical solutions consisting of the listed features and open technical solutions that include the listed features.

[0048] In this application, numerical intervals (i.e., numerical ranges) are involved. Unless otherwise specified, optional numerical distributions within the aforementioned numerical intervals are considered continuous and include the two endpoints (i.e., the minimum and maximum values) of the numerical range, as well as every value between these two endpoints. Unless otherwise specified, when a numerical interval refers only to integers within that interval, it includes the two endpoint integers of the numerical range, as well as every integer between the two endpoints. Furthermore, when multiple ranges are provided to describe features or characteristics, these ranges can be merged. In other words, unless otherwise specified, the ranges disclosed herein should be understood to include any and all subranges to which they are included.

[0049] In this application, weight can be a well-known unit of mass in the biological field, such as μg, mg, g, or kg.

[0050] As used in this application, the term "aryl" refers to an aromatic hydrocarbon group derived from an aromatic ring compound by removing one hydrogen atom. It can be a monocyclic aryl, a fused-ring aryl, or a polycyclic aryl; for polycyclic compounds, at least one is an aromatic ring system. For example, "C6~C6..." 20 "Aryl" refers to an aryl group containing 6 to 20 carbon atoms. Each time it appears, it can independently be a C6 aryl, C6 aryl, C6 aryl, or C6 aryl. 10 Aryl, C 14 Aryl, C 18 Aryl or C 20 Aryl group. Suitable examples include, but are not limited to: benzene, biphenyl, naphthalene, anthracene, phenanthrene, dinaphthalene, triphenylene and their derivatives. Understandably, multiple aryl groups may also be interrupted by short non-aromatic units (e.g., <10% non-H atoms, such as C, N or O atoms), specifically acenaphthene, fluorene, or 9,9-diarylfluorene, triarylamines, and diaryl ether systems should also be included in the definition of aryl.

[0051] As used in this application, the term "heteroaryl" refers to an aryl group in which at least one carbon atom is replaced by a non-carbon atom, which can be a nitrogen atom, an oxygen atom, a sulfur atom, etc. For example, "C3~C 10 "Heteroaryl" refers to a heteroaryl group containing 3 to 10 carbon atoms, which can be independently C3, C4, C5, C6, C7, or C8 heteroaryl each time it appears. Suitable examples include, but are not limited to: furan, benzofuran, thiophene, benzothiophene, pyrrole, pyrazole, triazole, imidazole, oxazole, oxadiazole, thiazole, tetrazolium, indole, carbazole, pyrroloimidazol, pyrrolopyrrole, thiophenolopyrrole, thiophenolothiophene, furanolopyrrole, furanolofuran, thiophenolofuran, benzoisoxazole, benzoisothiazolium, benzimidazole, pyridine, pyrazine, pyridazine, pyrimidine, triazine, quinoline, isoquinoline, o-diazonyl, quinoxaline, phenanthridine, primidine, quinazoline, and quinazolineone.

[0052] As used in this application, the term "alkyl" refers to a saturated hydrocarbon containing a primary (normal) carbon atom, or a secondary carbon atom, or a tertiary carbon atom, or a quaternary carbon atom, or a combination thereof. Phrases containing this term, such as "C1-C9 alkyl," refer to alkyl groups containing 1 to 9 carbon atoms, and each occurrence can independently be C1 alkyl, C2 alkyl, C3 alkyl, C4 alkyl, C5 alkyl, C6 alkyl, C7 alkyl, C8 alkyl, or C9 alkyl. Suitable examples include, but are not limited to: methyl (Me, -CH3), ethyl (Et, -CH2CH3), 1-propyl (n-Pr, n-propyl, -CH2CH2CH3), 2-propyl (i-Pr, i-propyl, -CH(CH3)2), 1-butyl (n-Bu, n-butyl, -CH2CH2CH2CH3), 2-methyl-1-propyl (i-Bu, i-butyl, -CH2CH(CH3)2), 2-butyl (s-Bu, s-butyl, -CH(C H3)CH2CH3), 2-methyl-2-propyl (t-Bu, t-butyl, -C(CH3)3), 1-pentyl (n-pentyl, -CH2CH2CH2CH2CH3), 2-pentyl (-CH(CH3)CH2CH2CH3), 3-pentyl (-CH(CH2CH3)2), 2-methyl-2-butyl (-C(CH3)2CH2CH3), 3-methyl-2-butyl (-CH(CH3)CH(CH3)2), 3-methyl-1-butyl (- CH2CH2CH(CH3)2), 2-methyl-1-butyl(-CH2CH(CH3)CH2CH3), 1-hexyl(-CH2CH2CH2CH2CH2CH3), 2-hexyl(-CH(CH3)CH2CH2CH2CH3), 3-hexyl(-CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl(-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl(-CH(CH3)CH( CH3)CH2CH3), 4-methyl-2-pentyl (-CH(CH3)CH2CH(CH3)2), 3-methyl-3-pentyl (-C(CH3)(CH2CH3)2), 2-methyl-3-pentyl (-CH(CH2CH3)CH(CH3)2), 2,3-dimethyl-2-butyl (-C(CH3)2CH(CH3)2), 3,3-dimethyl-2-butyl (-CH(CH3)C(CH3)3 and octyl (-(CH2)7CH3).

[0053] As used in this application, the term "cycloalkyl" refers to a non-aromatic hydrocarbon containing a ring of carbon atoms, which can be monocycloalkyl, spirocycloalkyl, or bridged cycloalkyl. Phrases containing this term, such as "C3-C9 cycloalkyl," refer to cycloalkyl compounds containing 3 to 9 carbon atoms, and each occurrence can independently be C3, C4, C5, C6, C7, C8, or C9 cycloalkyl. Suitable examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl. Additionally, "cycloalkyl" may also contain one or more double bonds; representative examples of cycloalkyl compounds containing double bonds include cyclopentenyl, cyclohexenyl, cyclohexadienyl, and cyclobutadienyl.

[0054] As used in this application, the term "alkoxy" refers to a group having an -O-alkyl group, i.e., an alkyl group as defined above connected to a parent nucleus via an oxygen atom. Phrases containing this term, such as "C1-C9 alkoxy," refer to alkyl moieties containing 1 to 9 carbon atoms, and each occurrence can be independently C1 alkoxy, C4 alkoxy, C5 alkoxy, C6 alkoxy, C7 alkoxy, C8 alkoxy, or C9 alkoxy. Suitable examples include, but are not limited to, methoxy (-O-CH3 or -OMe), ethoxy (-O-CH2CH3 or -OEt), and tert-butoxy (-OC(CH3)3 or -OtBu).

[0055] As used in this application, "alkene" refers to a group containing at least one unsaturated site, i.e., carbon-carbon sp. 2 Hydrocarbons with a double bond consisting of a positive, secondary, tertiary, or cyclic carbon atom. Phrases containing this term, such as "C2–C9 alkenyl," refer to alkenyl groups containing 2–9 carbon atoms, which, each time appearing, can independently be C2, C3, C4, C5, C6, C7, C8, or C9 alkenyl. Suitable examples include, but are not limited to: vinyl (-CH=CH2), allyl (-CH2CH=CH2), cyclopentenyl (-C5H7), and 5-hexenyl (-CH2CH2CH2CH2CH=CH2).

[0056] As used in this application, "alkynyl" refers to a hydrocarbon containing at least one unsaturated carbon atom, i.e., a carbon-carbon sp triple bond, or a cyclic carbon atom. Phrases containing this term, such as "C2-C9 alkenyl," refer to alkynyl groups containing 2 to 9 carbon atoms, and each occurrence can be independently C2-alkynyl, C3-alkynyl, C4-alkynyl, C5-alkynyl, C6-alkynyl, C7-alkynyl, C8-alkynyl, or C9-alkynyl. Suitable examples include, but are not limited to, ethynyl (-C≡CH) and propynyl (-CH2C≡CH).

[0057] In this application, the term "halogen" refers to fluorine (F), chlorine (Cl), bromine (Br), and iodine (I); "nitro" refers to -NO2; "carboxyl" refers to -COOH; "hydroxyl" refers to -OH; "thiol" refers to -SH; "amino" refers to -NH2; "cyano" refers to -CN; and "acyl" refers to -C(=O)-R. a The term "sulfonyl" indicates -S(=O)(=O)-R b "Aminoacyl"-C(=O)-NH2,R a and R b It is an alkyl group, and more specifically a C1 to C6 alkyl group, such as formyl, acetyl, propionyl, methanesulfonyl, ethanesulfonyl, propionyl, etc.

[0058] Any combination of the aforementioned groups in this application covers various suitable combinations of the aforementioned groups. For example, when the aforementioned groups are deuterium, halogen, nitro, carboxyl, hydroxy, hydroxymethyl, mercapto, amino, cyano, acyl, sulfonyl, aminoacyl, alkenyl, alkynyl, alkyl, cycloalkyl, alkoxy, or aryl, suitable combinations include hydroxyl-substituted alkyl groups (such as hydroxymethyl), halogen-substituted alkyl groups (such as trifluoromethyl), halogen-substituted alkoxy groups (such as trifluoromethoxy), alkyl-substituted amino groups (such as monomethylamino, dimethylamino, n-propylamino, isopropylamino), and alkyl-substituted mercapto groups (such as methimazole, ethimazole, n-propimazole, isopropimazole). In the above combinations, the alkyl group is further selected from alkyl groups having 1 to 6 carbon atoms.

[0059] As used in this application, the term "pharmaceutically acceptable" means that these compounds, materials, compositions, and / or dosage forms, when used in contact with human and animal tissues with reliable medical judgment, do not cause excessive toxicity, irritation, allergic reactions, or other problems or complications, in proportion to a reasonable benefit / risk ratio.

[0060] As used in this application, the term "pharmaceutically acceptable salt" refers to the salt form corresponding to the compounds of this application, prepared from compounds of this application with specific substituents by contacting them with a relatively non-toxic acid or base. When the compounds of this application contain relatively acidic groups, a base addition salt can be obtained by adding a sufficient amount of base to a solution to contact the neutral form of the compound. Pharmaceutically acceptable base addition salts include salts such as sodium, potassium, calcium, ammonium, organic amines, or magnesium salts. When the compounds of this application contain relatively basic groups, an acid addition salt can be obtained by adding a sufficient amount of acid to a solution to contact the neutral form of the compound. Pharmaceutically acceptable acid addition salts include inorganic acid salts and organic acid salts. Inorganic acids include hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, bicarbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, and hydrogen sulfate. Organic acids include acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, octanoic acid, lactic acid, mandelic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, tartaric acid, and methanesulfonic acid. The compounds in this application contain both basic and acidic functional groups, and can therefore be converted into any acid or base addition salt.

[0061] The term “enantiomeric excess” or “enantiomeric excess percentage ee%” as used in this application refers to the excess of one enantiomer over another, usually expressed as a percentage.

[0062] In a first aspect, embodiments of this application provide an aldolase, the amino acid sequence of which includes any one of (a1) to (a3):

[0063] (a1) The amino acid sequence as shown in SEQ ID No. 1;

[0064] (a2) A sequence based on the amino acid sequence shown in (a1) by substitution, deletion and / or insertion of one or more amino acids;

[0065] (a3) an amino acid sequence that has at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence homology with the amino acid sequence shown in (a1).

[0066] In the technical solutions of this application, the aldolases obtained through appropriate amino acid sequence design have a wider substrate applicability and higher catalytic efficiency, and can be used to catalyze the mild and efficient condensation of bromoethylone compounds and keto acids.

[0067] In some embodiments, when the amino acid sequence of the aldolase includes (a2), it is a sequence based on the amino acid sequence shown in (a1) by substitution, deletion and / or insertion of one or more amino acids.

[0068] For those skilled in the art, such substitution can occur in regions other than the aforementioned sites while retaining the corresponding activity. In some embodiments, the mutant following conserved substitution has at least one conserved amino acid substitution. Examples of conserved substitution include substitutions within the following amino acid groups: basic amino acids (such as arginine, lysine, and histidine), acidic amino acids (such as glutamic acid and aspartic acid), polar amino acids (such as glutamine and asparagine), hydrophobic amino acids (such as leucine, isoleucine, and valine), aromatic amino acids (such as phenylalanine, tryptophan, and tyrosine), and small molecule amino acids (such as glycine, alanine, serine, threonine, and methionine).

[0069] In some implementations, the conservative alternative is selected from the group consisting of G, A, V, L, I, F, P, S, T, H, W, C, D, E, K, Y, M, N, Q, and R.

[0070] In some embodiments, proteins that have a certain degree of homology similarity to the nucleotide sequences of the above-mentioned aldolase and transaminase, such as proteins with a homology similarity of 70% to 90%, further to 80% to 99%, and even further to 90% to 99%, as well as variants that have similar catalytic activity or catalytic efficiency to the original enzyme, are all included within the scope of protection of this application.

[0071] The "homology" (sequence identity percentage) of an amino acid sequence (or nucleic acid sequence) is defined as the percentage of amino acid (or nucleic acid) residues in a candidate sequence that are identical to those in a reference sequence after sequence alignment, and, where necessary, the introduction of vacancies to achieve the maximum number of identical amino acids (or nucleic acids). In other words, the sequence identity percentage (%) of an amino acid sequence (or nucleic acid sequence) can be calculated by dividing the number of identical amino acid residues (or bases) relative to the reference sequence by the total number of amino acid residues (or bases) in the candidate or reference sequence (whichever is shorter). Conservative substitutions of amino acid residues may or may not be considered identical residues. For example, publicly available tools can be used, such as BLASTN, BLASTp (available on the website of the US National Center for Biotechnology Information (NCBI), see also Altschul SF et al., Journal of Molecular Biology, 215:403-410 (1990); Stephen F. et al., Nucleic Acids Research, 25:3389-3402 (1997)), ClustalW2 (available on the website of the European Bioinformatics Institute, see also Higgins DG et al., Methods in Enzymology, 266:383-402 (1996); Larkin MA et al., *Bioinformatics* (Cambridge, UK), 23(21):2947-8 (2007)) and ALIGN or Megalign (DNASTAR) software can be used to perform alignments to determine the percentage of identity between amino acid (or nucleic acid) sequences. Those skilled in the art can use the default parameters provided by the tools or can appropriately customize the parameters as needed for the alignment, for example, by selecting a suitable algorithm.

[0072] See also Higgins DG et al., Methods in Enzymology, 266:383-402 (1996); Larkin MA et al., Bioinformatics (Cambridge, UK), 23(21):2947-8 (2007)); and ALIGN or Megalign (DNASTAR) software for alignments used to determine the percentage of identity of amino acid (or nucleic acid) sequences. Those skilled in the art can use the default parameters provided by the tools or can appropriately customize the parameters as needed for the alignment, for example, by selecting a suitable algorithm.

[0073] As used in this application, the term "amino acid" refers to a class of organic compounds containing amino (-NH2) and carboxyl (-COOH) functional groups. The names of amino acids are also represented in this application as standard single-letter or three-letter codes, summarized in Table 1.

[0074] Table 1. Standard single-letter and three-letter codes for amino acid names in this application.

[0075]

[0076] Secondly, embodiments of this application provide an enzyme composition comprising aldolase and transaminase as described above;

[0077] The amino acid sequence of transaminase includes any one of (b1) to (b3):

[0078] (b1) An amino acid sequence as shown in SEQ ID No. 2 or SEQ ID No. 3;

[0079] (b2) A sequence based on the amino acid sequence shown in (b1) by substitution, deletion and / or insertion of one or more amino acids;

[0080] (b3) An amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence homology to the amino acid sequence shown in (b1). In the technical solution of this application embodiment, the enzyme composition includes an aldolase as described above. The aldolase, obtained through suitable amino acid sequence design, catalyzes the mild and efficient condensation of bromoethylone compounds and keto acids to generate an α-keto acid intermediate. The α-keto acid intermediate is then converted into the corresponding 5-substituted pyrrole-2-carboxylic acid compound under the action of a transaminase, thus achieving the mild and efficient synthesis of 5-substituted pyrrole-2-carboxylic acid compounds.

[0081] In some embodiments, when the amino acid sequence of the transaminase includes (b2), which is a sequence based on the amino acid sequence shown in (b1) by substitution, deletion and / or insertion of one or more amino acids, the definition of "substitution, deletion and / or insertion of one or more amino acids" is given in (a2) above.

[0082] Thirdly, embodiments of this application provide a nucleic acid molecule that can encode the aldolase mentioned above.

[0083] In the technical solution of this application embodiment, the nucleic acid molecule can encode the aldolase mentioned above. The expression product of the nucleic acid molecule, namely the aldolase, has a wider substrate applicability and higher catalytic efficiency, and can be used to catalyze the mild and efficient condensation of bromoethylone compounds and keto acids.

[0084] In some embodiments, the nucleotide sequence of the nucleic acid molecule includes any one of (c1) to (c3):

[0085] (c1) The nucleotide sequence shown in SEQ ID NO.4;

[0086] (c2) and (c1) show nucleotide sequences that encode the same protein, but are different from the nucleotide sequence shown in (c1) due to the degeneracy of the genetic code;

[0087] (c3) is a nucleotide sequence obtained by substituting, deleting or adding one or more nucleotide sequences to the nucleotide sequence shown in (c1) or (c2), and is a nucleotide sequence that has the same or similar function as the nucleotide sequence shown in (c1) or (c2);

[0088] (c4) is a nucleotide sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence homology with the nucleotide sequences described in (c1), (c2), or (c3).

[0089] The nucleic acid molecule can also encode the transaminase mentioned above.

[0090] In some embodiments, the nucleotide sequence of the nucleic acid molecule further includes any one of (d1) to (d4):

[0091] (d1) Nucleotide sequences as shown in SEQ ID NO.5 or SEQ ID NO.6;

[0092] (d2) and (d1) show nucleotide sequences that encode the same protein, but are different from the nucleotide sequence shown in (d1) due to the degeneracy of the genetic code;

[0093] (d3) is a nucleotide sequence obtained by substituting, deleting or adding one or more nucleotide sequences to the nucleotide sequence shown in (d1) or (d2), and is functionally the same or similar to the nucleotide sequence shown in (d1) or (d2).

[0094] (d4) is a nucleotide sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence homology with the nucleotide sequences described in (d1), (d2), or (d3).

[0095] Fourthly, embodiments of this application provide a recombinant expression vector, expression cassette, or construct, including the nucleic acid molecule described above.

[0096] In some embodiments, the recombinant expression vector can be an Escherichia coli expression vector such as pACYCDuet-1, pET-28a, or pET-22b.

[0097] In the technical solutions of this application embodiment, the recombinant expression vector, expression cassette, or construct includes the nucleic acid molecules as described above. The recombinant expression vector, expression cassette, or construct can express the target aldolase in a suitable host. The aldolase has a wider substrate applicability and higher catalytic efficiency, and can be used to catalyze the mild and efficient condensation of bromoethylone compounds and keto acids.

[0098] Fifthly, embodiments of this application provide a host capable of transfecting or transforming recombinant expression vectors, expression cassettes, or constructs as described above.

[0099] In some embodiments, the host may be Escherichia coli or yeast.

[0100] In some embodiments, the host protein expression system and its application include the following steps: transforming a plasmid carrying gene sequences encoding aldolase and transaminase into competent *E. coli* cells, and using 0.1 mM isopropyl-β-... D -Galactothioglycoside (IPTG) was induced at 18°C ​​for 20 hours to express proteins. Both the pure enzyme systems and whole-cell systems of aldolase and transaminase exhibited catalytic activity within the range of 10°C to 50°C, optionally 15°C to 40°C, and more preferably 20°C to 30°C.

[0101] In the technical solution of this application embodiment, the host can be transfected or transformed with the recombinant expression vector, expression cassette or construct as described above to achieve the expression of the target aldolase. The aldolase has a wider substrate applicability and higher catalytic efficiency, and can be used to catalyze the mild and efficient condensation of bromoethylone compounds and keto acids.

[0102] In the technical solutions of this application embodiment, the aldolase and enzyme composition include aldolases with specific amino acid sequences. The nucleic acid molecules, recombinant expression vectors, expression cassettes, or constructs can respectively encode and express the corresponding aldolases. The host can be transfected or transformed with the recombinant expression vector, expression cassette, or construct to express the corresponding aldolase. Therefore, they can all be used to catalyze the mild and efficient condensation of bromoethylone compounds and keto acids to obtain α-keto acid intermediates. The α-keto acid intermediates are then converted into 5-substituted pyrrole-2-carboxylic acid compounds by transaminase, thereby realizing the biosynthesis of 5-substituted pyrrole-2-carboxylic acid compounds.

[0103] In a sixth aspect, embodiments of this application provide a method for preparing a 5-substituted pyrrole-2-carboxylic acid compound or a pharmaceutically acceptable salt thereof, comprising reacting the compound represented by Formula I with sodium pyruvate and glutamic acid in the presence of a cofactor and an enzyme catalyst to obtain the compound represented by Formula II;

[0104]

[0105] Ring A is selected from substituted or unsubstituted aryl or heteroaryl groups, wherein substitution refers to at least one hydrogen atom of ring A being substituted by R. a replace;

[0106] R a Each time it appears, it is independently selected from deuterium, halogen, nitro, carboxyl, hydroxyl, mercapto, amino, cyano, acyl, sulfonyl, aminoacyl, alkenyl, alkynyl, alkyl, cycloalkyl, alkoxy, aryl, or any combination of the aforementioned groups;

[0107] The enzyme catalyst consists of aldolase and transaminase, as mentioned above.

[0108] Alternatively, the transaminase is defined as in the second aspect.

[0109] The pharmaceutically acceptable salts described in this application can be obtained using conventional salt-forming methods in the art. For example, obtaining a pharmaceutically acceptable salt of a 5-substituted pyrrole-2-carboxylic acid compound involves adding a suitable base, acid, or salt solution to the 5-substituted pyrrole-2-carboxylic acid compound, followed by vacuum concentration to obtain the corresponding salt solution. Acid solutions include, but are not limited to, formic acid, acetic acid, hydrochloric acid, and nitric acid. Base solutions include, but are not limited to, sodium hydroxide, potassium hydroxide, lithium hydroxide, and ammonia. Salt solutions include, but are not limited to, hydrochloride, sulfate, nitrate, or phosphate.

[0110] Among them, the salt-forming sites in 5-substituted pyrrole-2-carboxylic acid compounds include, but are not limited to, amino (-NH2) and carboxyl (-COOH) groups. Understandably, when a 5-substituted pyrrole-2-carboxylic acid compound is mixed with an acid solution, the amino group in the 5-substituted pyrrole-2-carboxylic acid compound reacts with the acid in the acid solution to form a salt; when a 5-substituted pyrrole-2-carboxylic acid compound is mixed with a salt solution (e.g., a sodium salt solution), the carboxyl group in the 5-substituted pyrrole-2-carboxylic acid compound reacts with the salt ion to form a salt.

[0111] In some embodiments, ring A is a substituted or unsubstituted C6-C ring. 10 Aryl or C3-C8 heteroaryl, in the definition of substitution, substitution means that at least one hydrogen atom of the listed group is replaced by R. a Substitution. For example, a substituent R on a phenyl group.a The number can be 1, 2, 3, 4 or 5.

[0112] In some embodiments, ring A is a substituted or unsubstituted C6-C ring. 10 Aryl group, preferably substituted or unsubstituted phenyl group.

[0113] In some embodiments, ring A is a substituted or unsubstituted C3-C8 heteroaryl group, preferably with ≤2 heteroatoms. Further, the structure of the group includes at least one benzene ring, for example, benzofuranyl.

[0114] In some embodiments, ring A is selected from substituted or unsubstituted phenyl, benzofuranyl, thiophenyl, or pyridyl.

[0115] In some embodiments, R a The alkyl group is selected from halogen, cyano, alkyl, alkoxy, or halogen-substituted alkyl groups. For the definition of alkyl, please refer to the relevant terminology. Preferably, the alkyl group has 1 to 6 carbon atoms.

[0116] In some embodiments, the 5-substituted pyrrole-2-carboxylic acid compounds are selected from the compounds listed in Table 14.

[0117] In the preparation method of this application embodiment, the substitution-transamination reaction has catalytic activity within the pH range of 5.0-10.0.

[0118] Optionally, the pH value can be 5.0, 6.0, 7.0, 8.0, 9.0, 10.0, or a range between any two of the above values, such as 6.4.

[0119] Optionally, the substitution-transamination reaction time can be from 1 h to 48 h, for example 1 h, 5 h, 10 h, 20 h, 24 h, 40 h, 48 h, etc.

[0120] In some embodiments, substitution refers to bimolecular nucleophilic substitution (S... N 2. Substitution reaction).

[0121] In the technical solution of this application embodiment, an aldolase is used to catalyze the reaction of bromoethyl ketone compounds of Formula I with sodium pyruvate to form an S-type reaction. N The 2-substitution reaction generates a keto acid intermediate, which is then reacted with glutamic acid via transaminase catalysis to generate a 5-substituted pyrrole-2-carboxylic acid compound.

[0122] In this embodiment, the preparation method of 5-substituted pyrrole-2-carboxylic acid compounds is simple to operate, mild under mild conditions, has high catalytic efficiency and good stereoselectivity, and can obtain optically pure 5-substituted pyrrole-2-carboxylic acid compounds.

[0123] In some embodiments, the transaminase is TyrB or MsDAT.

[0124] In some embodiments, the cofactor includes pyridoxal phosphate.

[0125] In some embodiments, the molar ratio of the compound represented by Formula I, sodium pyruvate, and glutamic acid is 1:(1-10000):(1-10000).

[0126] In some embodiments, the method for obtaining the compound of formula II by reacting the compound of formula I with sodium pyruvate and glutamic acid in the presence of a cofactor and an enzyme catalyst includes method A and method B:

[0127] Method A includes the following steps:

[0128] (e1) Aldolase, the compound shown in Formula I, and sodium pyruvate are mixed in a first solution to obtain a first mixture. (e2) The first mixture is stirred at a first temperature for a first time, and then filtered to obtain the filtrate. (e3) Cofactor, transaminase, and glutamate are added to the filtrate and mixed to obtain a second mixture. (e4) The second mixture is stirred at a second temperature for a second time to obtain the compound shown in Formula II. The first temperature and the second temperature are independently selected from 20℃ to 50℃; the first time is from 1h to 48h, and the second time is from 1h to 48h.

[0129] Method B includes the following steps:

[0130] (f1) The host capable of expressing aldolase and transaminase, cofactor, compound shown in Formula I, sodium pyruvate and glutamate are mixed in the second solution to obtain a third mixture. (f2) The third mixture is stirred at a third temperature for a third time to obtain the compound shown in Formula II. The third temperature is 20℃~50℃ and the third time is 1h~48h.

[0131] The following provides a more detailed explanation of the two methods.

[0132] Method A:

[0133] In the technical solution of this application embodiment, method A involves the separation step of intermediate products. In (e1) to (e2), the compound shown in formula I and sodium pyruvate are subjected to a substitution reaction in the presence of aldolase to obtain a substituted product. The substituted product exists in solution, so it needs to be filtered to obtain a filtrate. In (e3), the substituted product is reacted with glutamic acid in the presence of cofactor and transaminase to obtain the compound shown in formula II.

[0134] In some embodiments, the mass concentration of aldolase in the first mixture is 0.05 mg / mL to 100 mg / mL, for example 0.05 mg / mL, 0.1 mg / mL, 0.5 mg / mL, 1 mg / mL, 5 mg / mL, 10 mg / mL, 50 mg / mL, 100 mg / mL, etc.

[0135] Furthermore, the mass concentration of aldolase in the first mixture was 0.1 mg / mL to 80 mg / mL.

[0136] Furthermore, the mass concentration of aldolase in the first mixture was 0.2 mg / mL to 40 mg / mL.

[0137] In some embodiments, the mass concentration of transaminase in the second mixture is 0.05 mg / mL to 100 mg / mL, for example 0.05 mg / mL, 0.1 mg / mL, 0.5 mg / mL, 1 mg / mL, 5 mg / mL, 10 mg / mL, 50 mg / mL, 100 mg / mL, etc.

[0138] Furthermore, the mass concentration of transaminase in the second mixture was 0.1 mg / mL to 80 mg / mL.

[0139] Furthermore, the mass concentration of transaminase in the second mixture was 0.2 mg / mL to 40 mg / mL.

[0140] In some embodiments, the molar concentration of the cofactor in the second mixture is 0.02 mM to 0.5 mM.

[0141] Method B:

[0142] In the technical solution of this application embodiment, method B does not require the separation of intermediate products and can achieve whole-cell synthesis. In (f1) to (f2), the host capable of expressing aldolase and transaminase, cofactor, compound shown in formula I, sodium pyruvate and glutamate are mixed in solution and reacted directly to obtain the compound shown in formula II.

[0143] In some embodiments, the whole-cell mass concentration of the enzyme-co-expressing composition in the third mixture is 15–25 mg / mL.

[0144] In some embodiments, the third mixture contains 10 mM of the compound shown in Formula I, 100 mM sodium pyruvate, 40 mM glutamate, 0.1 mM cofactor, and 20 mg / mL of lyophilized host capable of expressing aldolase and transaminase.

[0145] In some embodiments, the molar concentration of the cofactor in the third mixture is 0.02 mM to 0.5 mM.

[0146] In some embodiments, the first solution and the second solution each independently comprise a buffer solution; optionally, the buffer solution comprises at least one of phosphate buffer, Tris-HCl buffer, ammonium acetate buffer, and HEPES-NaOH buffer.

[0147] In some embodiments, the buffer solution is selected from phosphate buffer, containing 50 mM Na2HPO4·12H2O and 50 mM NaCl or containing 100 mM K2HPO4·3H2O.

[0148] In some embodiments, the first solution and the second solution each independently further include a co-solvent.

[0149] Optionally, the cosolvent includes at least one of dimethyl sulfoxide, methanol, ethanol and isopropanol.

[0150] In some embodiments, the cosolvent is selected from dimethyl sulfoxide.

[0151] Optionally, the co-solvent accounts for 5% to 25% of the volume of the first or second solution.

[0152] The following are some specific examples.

[0153] For experimental parameters not specified in the following specific embodiments, please refer to the guidelines given in this application document first, or refer to experimental manuals or other experimental methods known in the art, or refer to the experimental conditions recommended by the manufacturer.

[0154] The raw materials and reagents involved in the following specific embodiments can be obtained commercially or prepared by those skilled in the art using known methods.

[0155] The main reagents and consumables used in the embodiments of this application are as follows:

[0156] In this specific embodiment, all primer synthesis and gene sequencing were performed by GENEWIZ. The primer sequences and corresponding nucleotide sequences of the proteins used are listed in the sequence listing. In this embodiment, GENEWIZ was commissioned to optimize the codons and synthesize the gene sequences. The optimized DNA sequences were then cloned into the pET-28a vector, or cloned by the applicant into the desired target vector. The cloned plasmid sequences are also listed in the sequence listing. The competent cells of the expression strain E. coli BL21(DE3) were purchased from Shanghai Bioengineering Co., Ltd.

[0157] The antibiotics used in this application (kanamycin Kansei, chloramphenicol Cm), the culture medium components Tryptone, Yeastextract, NaCl, agar, and the protein expression inducer isopropyl β- D- Glucosinolate (IPTG) and BL21(DE3) competent cells were purchased from Sangon Biotech (Shanghai) Co., Ltd.; homologous recombinase (ClonExpress II One StepCloning Kit), DNA polymerase (2×Phanta Max Master Mix (Dye Plus), 2×Rapid Taq Master Mix), T4 DNA ligase (T4 DNA Ligase), agarose gel extraction kit, and nucleic acid dyes were purchased from Nanjing Novizan Biotechnology Co., Ltd.; plasmid extraction kit was purchased from Yisheng Biotechnology (Shanghai) Co., Ltd.; restriction endonucleases (Dpn I, Nde I, Xho I, BamHI, HindIII, etc.) and DNA markers were purchased from Takara Ltd.; three-color pre-stained protein markers and one-step PAGE gel rapid preparation kits were purchased from Shanghai Yamei Biotechnology Co., Ltd.; bromoacetophenone substrates in the reaction components, L -Glu / D -Glu and sodium pyruvate standards were purchased from Shanghai Bid Pharmaceutical Technology Co., Ltd.; cofactor pyridoxal phosphate (PLP) was purchased from J&K.

[0158] Luria-Bertani (LB) medium contains 10 g / L tryptone, 10 g / L NaCl, and 5 g / L yeast extract. Before sterilization, add 1.5–2 g / 100 mL of agar to the flask and autoclave at 121°C for 30 min. The Kan stock solution concentration is 50 mg / mL, and the Cm stock solution concentration is 35 mg / mL. Dissolve the solutions in sterile ddH2O, filter, and dispense into 1.5 mL EP tubes. Store at -20°C. When using, add 1‰ of the corresponding antibiotic to the LB medium.

[0159] The IPTG stock solution was prepared with sterile ddH2O at a concentration of 1M, filtered, and dispensed into 1.5mL EP tubes. It was stored at -20℃. During induction of expression, the IPTG stock solution was added to LB medium at a final concentration of 0.1mM.

[0160] Solutions required for SDS-PAGE: Protein electrophoresis buffer containing 1 g / L SDS, 6.06 g / L Tris, and 14.4 g / L Gly, dissolved in sterile ddH2O and adjusted to pH 8.3; Coomassie Brilliant Blue R-250 staining solution containing 2 g / L Coomassie Brilliant Blue R-250, dissolved in a mixture of 800 mL ethanol and 200 mL acetic acid; Destaining solution prepared according to a ratio of deionized water:ethanol:acetic acid = 5:4:1; Reagents required for gel preparation are all from the Yake One-Step PAGE Gel Rapid Preparation Kit (10%), prepared according to the instructions.

[0161] Agarose gel electrophoresis 50× TAE buffer contains Tris 242 g / L, EDTA 18.612 g / L, and acetic acid 57.1 mL / L. After mixing, adjust the pH to 8.3 and dilute with deionized water to 1× before use. 1% agarose gel is prepared by adding 1% (w / V) agarose to 1× TAE solution, heating to dissolve until clear, adding 10000× nucleic acid dye at 1 μL / 10 mL, cooling and solidifying before loading for electrophoresis.

[0162] The sequences involved in the embodiments of this application are as follows, and other sequences not listed can be found in the corresponding descriptions.

[0163] NahE aldolase E285V Amino acid sequence: (SEQ ID NO.1)

[0164] MLNKVIKTTRLTAEDINGAWTIMPTPSTPDASDWRSTNTVDLDETARIVEELIAAGVNGILSMGTFGECATLTWEEKRDYVSTVVETIRGRVPYFCGTTALNTREVIRQTRELIDIGANGTMLGVPMWVKMDLPTAVQFYRDVAGAVPEAAIAIYANPEAFKFDFP RPFWAEMSKIPQVVTAKYLGIGMLDLDLKLAPNIRFLPHEDDYYAAARINPERITAFWSGAMCGPATAIMLRDEVERAKSTGDWIKAISDDMRAADSTLFPRGDFSEFSKYNIGLVKARMDAAGWLKAGPCRPPYNLVPEDYLVGAQKSGKAWAALHAKYSK.

[0165] amino acid sequence of transaminase TyrB: (SEQ ID NO.2)

[0166] FQKVDAYAGDPILTLMERFKEDPRSDKVNLSIGLYYNEDGIIPQLQAVAEAEARLNAQPHGASLYLPMEGLNCYRHAIAPLLFGADHPVLKQQRVATIQTLGGSGALKVGADFLKRYFPESGVWVSDPTWENHVAIFAGAGFEVSTYPWYDEATNGVRFNDLLATLKTLPARSIVLLHPCCHNPTGADLTNDQWDAVIEILKARELIPFLDIAYQGFGAGMEEDAYAIRAIASAGLPALVSNSFSKIFSLYGERVGGLSVMCEDAEAAGRVLGQLKATVRRNYSSPPNFGAQVVAAVLNDEALKASWLAEVEEMRTRILAMRQELVKVLSTEMPERNFDYLLNQRGMFSYTGLSAAQVDRLREEFGVYLIASGRMCVAGLNTANVQRVAKAFAAVM.

[0167] Amino acid sequence of transaminase MsDAT: (SEQ ID NO.3)

[0168] HMKTLGYYNGKIGELDAMSIPMNDRSHWFGDGVYDAAPSRNYHVFALDEHIDRFFNSAALLDIVMPVTKEELRQLLDKLVHKLDTGDLFVYFQVTRGTGLRNHAFTPGPGNLWVMLFPSSWNEGEKPIDVITEEDKRFYFCNIKTLNLIPSVLAAEHAKRQGCEETIFYRHDGRVTECAHSNCHILKDGKLITAPADELILPGIARAHLIRKCKELGIGVSETPYYKEALFTADEVLVTSSSNFCLRVAHIDGQAVGGRAPELYERLRQSLVAEFLHATSDN.

[0169] Encoding aldolase NahE E285V nucleic acid sequence: (SEQ ID NO.4)

[0170] ATGCTGAACAAAGTGATTAAAACCACCCGCCTGACCGCGGAAGATATTAACGGCGCGTGGACCATTATGCCGACCCCGAGCACCCCGGATGCGAGCGATTGGCGCAGCACCAACACCGTGGATCTGGATGAAACCGCGCGCATTGTGGAAGAACTGATTGCGGCGGGCGTGAACGGCATTCTGAGCATGGGCACCTTTGGCGAATGCGCGACCCTGACCTGGGAAGAAAAACGCGATTATGTGAGCACCGTGGTGGAAACCATTCGCGGCCGCGTGCCGTATTTTTGCGGCACCACCGCGCTGAACACCCGCGAAGTGATTCGTCAGACCCGCGAACTGATTGATATTGGCGCGAACGGCACCATGCTGGGCGTGCCGATGTGGGTGAAAATGGATCTGCCGACCGCGGTGCAGTTTTATCGCGATGTGGCGGGCGCGGTGCCGGAAGCGGCGATTGCGATTTATGCGAACCCGGAAGCGTTTAAATTTGATTTTCCGCGCCCGTTTTGGGCGGAAATGAGCAAAATTCCGCAAGTGGTGACCGCGAAATATCTGGGCATTGGCATGCTGGATCTGGATCTGAAACTGGCGCCGAACATTCGCTTTCTGCCGCATGAAGATGATTATTATGCGGCCGCGCGCATTAACCCGGAACGCATTACCGCGTTTTGGAGCAGCGGCGCGATGTGCGGCCCGGCGACCGCGATTATGCTGCGCGATGAAGTGGAACGCGCGAAAAGCACCGGCGATTGGATTAAAGCGAAAGCGATTAGCGATGATATGCGCGCGGCGGATAGCACCCTGTTTCCGCGCGGCGATTTTAGCGAATTTAGCAAATATAACATTGGCCTGGTTAAAGCGCGCATGGATGCGGCGGGCTGGCTGAAAGCGGGCCCGTGCCGCCCGCCGTATAACCTGGTGCCGGAAGATTATCTGGTGGGCGCGCAGAAAAGCGGCAAAGCGTGGGCGGCGCTGCATGCGAAATATAGCAAATA。

[0171] The nucleic acid sequence encoding the transaminase TyrB: (SEQ ID NO.5)

[0172]

[0173] Nucleic acid sequence encoding transaminase MsDAT: (SEQ ID NO.6)

[0174] ATGAAAACCCTGGGCTATTATAACGGCAAAATTGGCGAACTGGATGCGATGAGCATTCCGATGAACGATCGCAGCCATTGGTTTGGCGATGGCGTGTATGATGCGGCGCCGAGCCGCAACTATCATGTGTTTGCGCTGGATGAACATATTGATCGCTTTTTTAACAGCGCGGCGCTGCTGGATATTGTGATGCCGGTGACCAAAGAAGAACTGCGTCAGCTGCTGGATAAACTGGTGCATAAACTGGATACCGGCGATCTGTTTGTGTATTTTCAAGTGACCCGCGGCACCGGCCTGCGCAACCATGCGTTTACCCCGGGCCCGGGCAACCTGTGGGTGATGCTGTTTCCGAGCAGCTGGAACGAAGGCGAAAAACCGATTGATGTGATTACCGAAGAAGATAAACGCTTTTATTTTTGCAACATTAAAACCCTGAACCTGATTCCGAGCGTGCTGGCGGCGGAACATGCGAAACGCCAAGGCTGCGAAGAAACCATTTTTTATCGCCATGATGGCCGCGTGACCGAATGCGCGCATAGCAACTGCCATATTCTGAAAGATGGCAAACTGATTACCGCGCCGGCGGATGAACTGATTCTGCCGGGCATTGCGCGCGCGCATCTGATTCGCAAATGCAAAGAACTGGGCATTGGCGTGAGCGAAACCCCGTATTATAAAGAAGCGCTGTTTACCGCGGATGAAGTGCTGGTGACGAGCAGTAGCAACTTTTGCTTACGTGTTGCGCATATTGATGGCCAAGCGGTGGGCGGCCGCGCGCCGGAACTGTATGAACGCCTGCGTCAGAGCCTGGTGGCGGAATTTCTGCATGCGACGAGCGATAACTAA。

[0175] Example 1 Construction of aldolase and transaminase co-expression plasmid for cascade catalysis

[0176] In order to construct such Figure 1a and Figure 1b The cascade pathway for the synthesis of 5-substituted pyrrole-2-carboxylic acid compounds shown requires the heterologous co-expression of aldolase and transaminase within E. coli BL21(DE3).

[0177] First, the aldolase was cloned using pET-28a-NahE. E285V Using plasmids as templates, in NahE E285V The two ends are connected to BamHI and HindIII restriction sites. The reaction system is shown in Table 2, and the reaction procedure is shown in Table 3. In the tables below, phrases such as "fill to 40" and "fill to 20" refer to the substance used as a volume-fixing agent. This substance is added to the container after all other substances have been added until the total volume reaches the specified volume. For example, in Table 2, "ddH2O fill to 40 (μL)" means that after adding 2×PhantaMax Master Mix (Dye Plus) and NahE... E285V In graduated containers containing Template, BamHⅠ Primer, and HindⅢ Primer, add ddH2O as a final volume stabilizer until the total volume reaches 40 μL.

[0178] Table 2 PCR amplification reaction system (40 μL)

[0179]

[0180]

[0181] Table 3 PCR amplification reaction procedure

[0182]

[0183] PCR amplification samples were subjected to nucleic acid electrophoresis at 140V for 30 min, and NahE containing BamHI and HindIII restriction sites was recovered. E285V Long segment.

[0184] The NahE obtained above E285V Using the long fragment and the pACYCDuet-1 empty vector synthesized by GENEBI as templates, double digestion with BamHⅠ and HindⅢ was performed. The reaction system is shown in Table 4.

[0185] Table 4. Double enzyme digestion reaction system (20 μL)

[0186]

[0187] Sequence of empty vector plasmid pACYCDuet-1: (SEQ ID NO.7)

[0188]

[0189] The above system was reacted in a PCR instrument at 37℃ for 2 h. The digested samples were subjected to nucleic acid electrophoresis at 140V for 30 min, and NahE enzymes with BamHI and HindIII restriction sites at both ends were recovered. E285V Short gene fragments and linearized pACYCDuet-1 plasmids were stored at -20℃ for later use.

[0190] The recovered products after double enzyme digestion were used for T4 DNA ligation according to the system shown in Table 5.

[0191] Table 5. T4 DNA ligation system (20 μL)

[0192]

[0193] The T4 DNA ligation system was incubated at 16℃ for 10–12 h. The ligation product was transformed into E. coli BL21(DE3) competent cells using the heat shock method. After culturing at 37℃ for 12 h, transformants were picked, and colony verification PCR was performed using pA-MCS-1-F / R-Primer. Single clones with correct DNA fragment size were selected for further culture, plasmid extraction, and sequencing verification. This step involved NahE… E285V The gene was ligated to MCS-1 of the pACYCDuet-1 plasmid. The colony validation PCR reaction system is shown in Table 6, and the reaction procedure is shown in Table 7.

[0194] Table 6. Single colony PCR validation reaction system (20 μL)

[0195]

[0196] Table 7. Single Colony PCR Validation Reaction Procedure

[0197]

[0198] pACYCDuet-NahE E285V The pET-28a-TyrB / pET-28a-MsDAT template was used in a double enzyme digestion reaction system, a T4 DNA ligation reaction system, and a colony verification PCR reaction system. The restriction enzyme sites were Nde I and Xho I, and the verification primers were pA-MCS-2-F / R-Primer. After nucleic acid electrophoresis at 140V for 30 min, single clones with correct DNA fragment size were picked and cultured. Plasmids were extracted and sequenced for verification. This step ligated the TyrB / MsDAT gene to the MCS-2 position of the pACYCDuet-1 plasmid.

[0199] The aldolase NahE can be obtained through the above steps. E285VCo-expression plasmid pACYCDuet-NahE with transaminase TyrB / MsDAT E285V -TyrB / pACYCDuet-NahE E285V -MsDAT( Figure 2 ).

[0200] The amplification primers and validation primers are shown in Table 8.

[0201] Table 8. Amplification and verification primer sequences

[0202]

[0203] Example 2: Reaction system for whole-cell catalytic synthesis of 5-substituted pyrrole-2-carboxylic acid compounds

[0204] This embodiment verifies the feasibility of this cascade pathway in whole-cell catalysis, using pACYCDuet-NahE containing the target gene sequence. E285V -TyrB / pACYCDuet-NahE E285V Using MsDAT freeze-dried Escherichia coli BL21(DE3) as a catalyst and 10 mM 2-bromoacetophenone as a substrate, the reaction system shown in Table 9 was verified.

[0205] Table 9. Whole-cell catalytic reaction validation system (2 mL)

[0206]

[0207] The reaction was carried out with stirring at room temperature, and samples were taken at 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, 12 h, and 24 h to monitor the reaction progress. The peak area of ​​the product (5-substituted pyrrole-2-carboxylic acid compound) in the samples at each time point was analyzed by UPLC-MS, and a standard curve of product concentration versus peak area was plotted using product standards. The product concentration at each time point was then calculated, and the conversion rate was further deduced.

[0208] Detection method for reaction samples: Quench 10 μL of reaction solution with 190 μL of 50% methanol, mix well, centrifuge and take the supernatant.

[0209] UPLC-MS detection conditions: Column: ACQUITY BEH C18 (2.1×50mm, 1.7μm); Mobile phase: water (0.1% formic acid) / acetonitrile (0.1% formic acid); Gradient: 5%–95%; Acquisition time: 4.5 min; Flow rate: 0.8 mL / min; Column temperature: 40℃; Injection: 5 μL. Figure 3 5-Substituted-pyrrole-2-carboxylic acid compounds were shown. LUPLC-MS detection results of -Ⅱ1 Figure 4 Demonstrates whole-cell catalysis L The reaction progress curve of -Ⅱ1 shows that the conversion rate of the substrate 2-bromoacetophenone is as high as 70% at 24h, which proves the feasibility of the whole-cell cascade catalytic pathway constructed in this application.

[0210] Example 3: Reaction system for the in vitro cascade catalytic synthesis of 5-substituted pyrrole-2-carboxylic acid compounds using aldolase and transaminase.

[0211] In this embodiment, an in vitro cascade catalytic reaction was carried out using aldolase and transaminase to synthesize 5-substituted pyrrole-2-carboxylic acid compounds. The in vitro cascade catalytic reaction was carried out in two steps, and the substitution reaction system of the first step is shown in Table 10.

[0212] Table 10. In vitro cascade catalytic reaction verification system - substitution reaction (2 mL)

[0213]

[0214] The reaction was carried out with stirring at room temperature for 2 hours. After the 2-bromoacetophenone substrate was completely reacted, the second step of transamination reaction was carried out. The system is shown in Table 11.

[0215] Table 11. In vitro cascade catalytic reaction verification system - transamination reaction

[0216]

[0217] The reaction was carried out with stirring at room temperature. Samples were taken at 5 min, 10 min, 20 min, 40 min, 60 min, 120 min, 180 min, 240 min, 300 min, and 360 min to monitor the reaction progress. The peak area of ​​the product (5-substituted pyrrole-2-carboxylic acid compound) in the samples at each time point was analyzed by UPLC-MS, and a standard curve of product concentration versus peak area was plotted using product standards. The product concentration at each time point was calculated, and the conversion rate was further deduced.

[0218] Detection method for reaction samples: Quench 10 μL of reaction solution with 190 μL of 50% methanol, mix well, centrifuge and take the supernatant.

[0219] UPLC-MS detection conditions: Column: ACQUITY BEH C18 (2.1×50mm, 1.7μm); Mobile phase: water (0.1% formic acid) / acetonitrile (0.1% formic acid); Gradient: 5%–95%; Acquisition time: 4.5 min; Flow rate: 0.8 mL / min; Column temperature: 40℃; Injection: 5 μL. Figure 5 In vitro cascade catalysis was demonstrated LThe reaction progress curve of -Ⅱ1 shows that the conversion rate of the substrate 2-bromoacetophenone is as high as 94% at 6h, which proves the feasibility of the in vitro cascade catalytic pathway constructed in this application.

[0220] Example 4 Aldolase NahE E285V NahE E285A and NahE E285S Catalytic substitution reaction system

[0221] In this embodiment, the aldolase NahE is used. E285V NahE was obtained by replacing the amino acid sequence. E285A NahE E285S

[0222] NahE aldolase E285A Amino acid sequence: (SEQ ID NO.14)

[0223] MLNKVIKTTRLTAEDINGAWTIMPTPSTPDASDWRSTNTVDLDETARIVEELIAAGVNGILSMGTFGECATLTWEEKRDYVSTVVETIRGRVPYFCGTTALNTREVIRQTRELIDIGANGTMLGVPMWVKMDLPTAVQFYRDVAGAVPEAAIAIYANPEAFKFDFP RPFWAEMSKIPQVVTAKYLGIGMLDLDLKLAPNIRFLPHEDDYYAAARINPERITAFWSGAMCGPATAIMLRDEVERAKSTGDWIKAKAISDDMRAADSTLFPRGDFSEFSKYNIGLAKARMDAAGWLKAGPCRPPYNLVPEDYLVGAQKSGKAWAALHAKYSK.

[0224] NahE aldolase E285S Amino acid sequence: (SEQ ID NO.15)

[0225] MLNKVIKTTRLTAEDINGAWTIMPTPSTPDASDWRSTNTVDLDETARIVEELIAAGVNGILSMGTFGECATLTWEEKRDYVSTVVETIRGRVPYFCGTTALNTREVIRQTRELIDIGANGTMLGVPMWVKMDLPTAVQFYRDVAGAVPEAAIAIYANPEAFKFDFP RPFWAEMSKIPQVVTAKYLGIGMLDLDLKLAPNIRFLPHEDDYYAAARINPERITAFWSGAMCGPATAIMLRDEVERAKSTGDWIKAISDDMRAADSTLFPRGDFSEFSKYNIGLSKARMDAAGWLKAGPCRPPYNLVPEDYLVGAQKSGKAWAALHAKYSK.

[0226] It can be used for catalytic substitution reactions to synthesize keto acid intermediates, and the reaction system is shown in Table 12.

[0227] Table 12 Aldolase NahE E285V NahE E285A NahE E285S Catalytic substitution reaction (2 mL)

[0228]

[0229] The reaction was carried out with stirring at room temperature, and samples were taken after 2 hours to detect the reaction progress.

[0230] Detection method for reaction samples: Quench 10 μL of reaction solution with 190 μL of 50% methanol, mix well, centrifuge and take the supernatant.

[0231] UPLC-MS detection conditions: Column: ACQUITY BEH C18 (2.1×50mm, 1.7μm); Mobile phase: water (0.1% formic acid) / acetonitrile (0.1% formic acid); Gradient: 5%–95%; Acquisition time: 4.5 min; Flow rate: 0.8 mL / min; Column temperature: 40℃; Injection: 5 μL. Figure 7 NahE was displayed E285V NahE E285A and NahE E285S The catalytic results show that the aldolase obtained by site substitution based on the amino acid sequence shown in SEQ ID No. 1 still has catalytic activity in the substitution reaction of this application.

[0232] Example 5 Aldolase NahE wt Substitution reaction system catalyzed by homologous enzyme PhdJ

[0233] In this embodiment, the aldolase NahE is used. wt and homologous enzyme PhdJ ( Figure 8 Catalytic substitution reaction was used to synthesize keto acid intermediates. The reaction system is shown in Table 13.

[0234] NahE aldolase wt Amino acid sequence: (SEQ ID NO.16)

[0235] MLNKVIKTTRLTAEDINGAWTIMPTPSTPDASDWRSTNTVDLDETARIVEELIAAGVNGILSMGTFGECATLTWEEKRDYVSTVVETIRGRVPYFCGTTALNTREVIRQTRELIDIGANGTMLGVPMWVKMDLPTAVQFYRDVAGAVPEAAIAIYANPEAFKFDFP RPFWAEMSKIPQVVTAKYLGIGMLDLDLKLAPNIRFLPHEDDYYAAARINPERITAFWSGAMCGPATAIMLRDEVERAKSTGDWIKAKAISDDMRAADSTLFPRGDFSEFSKYNIGLEKARMDAAGWLKAGPCRPPYNLVPEDYLVGAQKSGKAWAALHAKYSK.

[0236] Amino acid sequence of homozyme PhdJ: (SEQ ID NO.17)

[0237] MHVRDTKLTVDDITGVVGIIPTPSIPTADQPGTAFSVDLDEAATLADAMVRGGVDVLMTTGTFGECASLTWDELQSFVATVVDAVAGRIPVFAGATTLNTRDTIARGRRLGELGADGLFVGRPMWLPLDDAGIVRFYRDVAEAVPNMALVVYDNPGAFKGKIGTPAY EALSQIPQVVAAKHLGLLSGSAFLSDLRAVSGRVRLLPLETDWYYFARLFPEEVTACWSGNVACGPAPVTHLRDLIRARRWDDCQALTDELEGALETLYPGGNFAEFLKYSIQIDNAQFQAAGFMRTGPTRPPYTEVPESYLAGGREAGKNWAALQQRYASLAVSNH.

[0238] Table 13. PhdJ-catalyzed substitution reactions of homologous enzymes (2 mL)

[0239]

[0240] The reaction was carried out with stirring at room temperature, and samples were taken after 2 hours to detect the reaction progress.

[0241] Detection method for reaction samples: Quench 10 μL of reaction solution with 190 μL of 50% methanol, mix well, centrifuge and take the supernatant.

[0242] UPLC-MS detection conditions: Column: ACQUITY BEH C18 (2.1×50mm, 1.7μm); Mobile phase: water (0.1% formic acid) / acetonitrile (0.1% formic acid); Gradient: 5%–95%; Acquisition time: 4.5 min; Flow rate: 0.8 mL / min; Column temperature: 40℃; Injection: 5 μL. Figure 9 NahE was displayed wt PhdJ and NahE E285V The catalytic results show that wild-type NahE does not exhibit catalytic activity under the substitution reaction conditions described in this application, while PhdJ still exhibits catalytic activity in the reaction.

[0243] Example 6 Purification and characterization of 5-substituted pyrrole-2-carboxylic acid compounds

[0244] After the reaction was completed, the reaction solution was immediately frozen with liquid nitrogen, and then lyophilized using a freeze dryer. An appropriate amount of deionized water was added to the lyophilized residue, and the target compound was extracted using ultrasound-assisted extraction. The extract was then processed... Rapid preparative liquid chromatography (column: SD-0000-080, 80g) was used for separation and purification. Gradient elution was performed using a methanol-water system (both methanol and aqueous phases contained 1‰ formic acid). The fraction containing the target product was collected, and the solvent was removed using a rotary evaporator. The purified product was weighed and the yield was calculated. The yield calculation formula is: Product yield = (Actual product mass / Theoretical product mass) × 100%.

[0245] Take an appropriate amount of the purified product, dissolve it with deuterated reagent, and collect the solution. 1 H NMR, 13 C NMR and fluorine-containing compounds 19 FNMR NMR spectra were used, combined with high-resolution mass spectrometry to identify the structures of similar compounds. Compound yield and enantiomeric excess (ee) were calculated as follows: Figure 6 As shown.

[0246] The NMR data and high-resolution mass spectrometry data of the 40 5-substituted pyrrole-2-carboxylic acid compounds obtained in this application are summarized in Table 14.

[0247] Table 14. NMR and high-resolution mass spectrometry data for the whole-cell catalytic preparation of 5-substituted pyrrole-2-carboxylic acid compounds.

[0248]

[0249]

[0250]

[0251]

[0252]

[0253]

[0254] Example 7: Whole-cell catalytic system used for L Gram-scale preparation of -Ⅱ20

[0255] According to the methods described in Examples 2 and 3, for L -Ⅱ20 was prepared on a gram-scale basis with a yield of 55% and a production rate of 1.04 g / L.

[0256] The technical features of the above embodiments can be combined in any way. For the sake of brevity, not all possible combinations of the technical features in the above embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0257] The embodiments described above are merely illustrative of several implementation methods of this application, and while the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the patent application. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of this application, and these all fall within the protection scope of this application. Therefore, the protection scope of this patent application should be determined by the appended claims, and the specification and drawings can be used to interpret the content of the claims.

[0258] All references to this application are incorporated herein by reference as if each document were individually incorporated herein by reference. Unless they conflict with the purpose and / or technical solution of this application, all cited references are incorporated herein by reference in their entirety and for all purposes. When references are cited in this application, the definitions of relevant technical features, terms, nouns, phrases, etc., are also incorporated herein by reference. Examples and preferred embodiments of the cited technical features may also be incorporated herein by reference, but only to the extent that they enable the implementation of this application. It should be understood that when the cited content conflicts with the description in this application, this application shall prevail or modifications shall be made adaptably to the description in this application.

Claims

1. An aldolase, characterized in that, The amino acid sequence of the aldolase includes any one of (a1) to (a3): (a1) The amino acid sequence as shown in SEQ ID No. 1; (a2) A sequence based on the amino acid sequence shown in (a1) by substitution, deletion and / or insertion of one or more amino acids; and (a3) ​​An amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence homology with the amino acid sequence shown in (a1).

2. An enzyme composition, characterized in that, The enzyme composition comprises the aldolase and transaminase as described in claim 1; Optionally, the amino acid sequence of the transaminase includes any one of (b1) to (b3): (b1) An amino acid sequence as shown in SEQ ID No. 2 or SEQ ID No. 3; (b2) A sequence based on the amino acid sequence shown in (b1) by substitution, deletion and / or insertion of one or more amino acids; as well as (b3) An amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence homology with the amino acid sequence shown in (b1).

3. A nucleic acid molecule, characterized in that, The nucleic acid molecule is capable of encoding the aldolase described in claim 1.

4. The nucleic acid molecule as described in claim 3, characterized in that, The nucleotide sequence of the nucleic acid molecule includes any one of (c1) to (c3): (c1) The nucleotide sequence shown in SEQ ID NO.4; (c2) and (c1) show nucleotide sequences that encode the same protein, but are different from the nucleotide sequence shown in (c1) due to the degeneracy of the genetic code; (c3) is a nucleotide sequence obtained by substituting, deleting, or adding one or more nucleotide sequences to the nucleotide sequence shown in (c1) or (c2), and is functionally identical or similar to the nucleotide sequence shown in (c1) or (c2); and, (c4) is a nucleotide sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence homology with the nucleotide sequences described in (c1), (c2), or (c3).

5. The nucleic acid molecule according to claim 3, characterized in that, The nucleic acid molecule can also encode the transaminase as defined in claim 2.

6. The nucleic acid molecule according to claim 5, characterized in that, The nucleotide sequence of the nucleic acid molecule also includes any one of (d1) to (d4): (d1) Nucleotide sequences as shown in SEQ ID NO.5 or SEQ ID NO.6; (d2) and (d1) show nucleotide sequences that encode the same protein, but are different from the nucleotide sequence shown in (d1) due to the degeneracy of the genetic code; (d3) A nucleotide sequence obtained by substituting, deleting, or adding one or more nucleotide sequences to the nucleotide sequence shown in (d1) or (d2), and having the same or similar function as the nucleotide sequence shown in (d1) or (d2); and, (d4) is a nucleotide sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence homology with the nucleotide sequences described in (d1), (d2), or (d3).

7. A recombinant expression vector, expression cassette, or construct, characterized in that, Includes nucleic acid molecules as described in any one of claims 3 to 6.

8. The host, characterized in that, The host can be transfected or transformed with the recombinant expression vector, expression cassette or construct as described in claim 7. A method for preparing 9,5-substituted pyrrole-2-carboxylic acid compounds or pharmaceutically acceptable salts thereof, characterized in that, This includes reacting the compound shown in Formula I with sodium pyruvate and glutamic acid in the presence of cofactors and enzyme catalysts to obtain the 5-substituted pyrrole-2-carboxylic acid compound shown in Formula II through a substitution-transamination cascade reaction. Ring A is selected from substituted or unsubstituted aryl or heteroaryl groups, wherein substitution refers to at least one hydrogen atom of ring A being substituted by R. a replace; R a Each time it appears, it is independently selected from deuterium, halogen, nitro, carboxyl, hydroxyl, mercapto, amino, cyano, acyl, sulfonyl, aminoacyl, alkenyl, alkynyl, alkyl, cycloalkyl, alkoxy, aryl, or any combination of the aforementioned groups; The enzyme catalyst comprises transaminase and the aldolase as described in claim 1.

10. The preparation method according to claim 9, characterized in that, The transaminase includes the transaminase defined in claim 2.